PriceTargets.com logo

Cingulate - CING Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.50
  • Forecasted Upside: 597.97%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.94 As of 12/4/2025 05:00 PM ET
▼ -0.01 (-0.25%)

This chart shows the closing price for CING by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cingulate Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CING and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CING

Analyst Price Target is $27.50
▲ +597.97% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cingulate in the last 3 months. The average price target is $27.50, with a high forecast of $62.00 and a low forecast of $12.00. The average price target represents a 597.97% upside from the last price of $3.94.

This chart shows the closing price for CING for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Cingulate. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2025Roth CapitalLower TargetBuy ➝ Buy$17.00 ➝ $16.00
10/15/2025Roth CapitalBoost TargetBuy ➝ Buy$10.00 ➝ $17.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/22/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$61.00 ➝ $62.00
8/8/2025Roth CapitalReiterated RatingBuy ➝ Buy
5/27/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$60.00 ➝ $61.00
5/19/2025Roth CapitalSet TargetBuy ➝ Buy$12.00 ➝ $11.00
4/21/2025Ascendiant Capital MarketsLower TargetBuy ➝ Buy$75.00 ➝ $60.00
3/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
1/30/2025HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $20.00
1/10/2025Roth CapitalUpgradeStrong-Buy
1/10/2025Roth MkmInitiated CoverageBuy$12.00
11/20/2024Maxim GroupUpgradeHold ➝ Buy
1/5/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00
12/22/2023LaidlawDowngradeBuy ➝ Hold
12/18/2023Maxim GroupReiterated RatingBuy ➝ Hold
9/26/2023HC WainwrightLower TargetBuy ➝ Buy$110.00 ➝ $70.00
1/17/2023HC WainwrightReiterated RatingBuy
11/22/2022Maxim GroupInitiated CoverageBuy
10/3/2022Ascendiant Capital MarketsInitiated CoverageBuy
1/20/2022LaidlawInitiated CoverageBuy$170.00
1/11/2022AegisInitiated CoverageBuy$180.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 2 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
Mentions as of
9/5/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cingulate logo
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Read More

Today's Range

Now: $3.94
Low: $3.80
High: $3.98

50 Day Range

MA: $3.78
Low: $3.33
High: $4.35

52 Week Range

Now: $3.94
Low: $3.20
High: $6.01

Volume

137,422 shs

Average Volume

117,812 shs

Market Capitalization

$26.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cingulate?

The following Wall Street sell-side analysts have issued research reports on Cingulate in the last year: Ascendiant Capital Markets, HC Wainwright, Roth Capital, Roth Mkm, and Weiss Ratings.
View the latest analyst ratings for CING.

What is the current price target for Cingulate?

0 Wall Street analysts have set twelve-month price targets for Cingulate in the last year. Their average twelve-month price target is $27.50, suggesting a possible upside of 598.0%. Ascendiant Capital Markets has the highest price target set, predicting CING will reach $62.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $12.00 for Cingulate in the next year.
View the latest price targets for CING.

What is the current consensus analyst rating for Cingulate?

Cingulate currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CING.

What other companies compete with Cingulate?

Other companies that are similar to Cingulate include Zhengye Biotechnology, Anebulo Pharmaceuticals, Invizyne Technologies, Karyopharm Therapeutics and Atara Biotherapeutics. Learn More about companies similar to Cingulate.

How do I contact Cingulate's investor relations team?

The company's listed phone number is 913-942-2300 and its investor relations email address is [email protected]. The official website for Cingulate is www.cingulate.com. Learn More about contacing Cingulate investor relations.